Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies HMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with pembrolizumab SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 7, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative...
Source: philippinetimes.com